Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Clin Lung Cancer. 2020 Jul 3;21(6):553–561.e1. doi: 10.1016/j.cllc.2020.06.025

Table 4.

Listing of at Least Possibly Related to Pemetrexed Grade 3 and 4 Adverse Events.

Adverse Events Grade 3 Grade 4
n (%) n (%)
Hematologic Adverse Events
Anemia 2 (7%) 0 (0%)
Lymphocyte count decreased 2 (7%) 0 (0%)
Neutrophil count decreased 0 (0%) 1 (4%)
Platelet count decreased 1 (4%) 0 (0%)
Non-Hematologic Adverse Events
Fatigue 1 (4%) 0 (0%)
Anorectal infection 1 (4%) 0 (0%)
Skin infection 1 (4%) 0 (0%)
Hyperglycemia 2 (7%) 0 (0%)
Hypernatremia 1 (4%) 0 (0%)
Peripheral sensory neuropathy 1 (4%) 0 (0%)